期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯沙坦联合辛伐他汀治疗早期糖尿病肾病的临床观察 被引量：8

Clinical Observation on Early Diabetic Nephropathy Treated with Lovastain and Simvastatin
暂未订购
导出
摘要 目的观察氯沙坦联合辛伐他汀治疗早期糖尿病肾病的临床疗效及作用机制。方法 89例2型糖尿病合并早期糖尿病肾病及血脂异常患者,随机分为单用氯沙坦组(对照组)和氯沙坦联用辛伐他汀组(观察组),观察治疗前后2个月两组患者血脂、尿白蛋白排泄率(UAER)及C反应蛋白的变化情况。结果治疗2个月后,两组尿白蛋白排泄率均明显下降,观察组尿白蛋白排泄率、血清TC、血TG、血清LDL和血清C反应蛋白的下降明显优于对照组(P<0.05)。结论氯沙坦与辛伐他汀联用治疗早期DN可明显降低UAER,还具有一定的调脂和抗炎作用。 Objective To observe the clinical effiency of lovastain combined simvastatin on early diabetic nephropathy.Methods 89 patients with early diabetic nephropathy and dyslipidemia were randomly divided into control group and observation group.UAER,TG,TC,LDL and CRP in the patients were observed and compared before and after treatment between the observation group by combining treatment using lovastain and simvastatin for two months,and the control group by lovastain alone.Results The level of UAER was decreased significantly in two groups,and compared with the control group,the levels of UAER,TG,TC,LDL and CRP of patients in the observation group decreased significantly（P0.01）.Conclusion The combination therapy of lovastain and simvastatin has good effect on decreasing UAER and reducing lipidemia.
作者 曹蕾 徐将
机构地区 安徽省蒙城县第一人民医院内科 安徽省立医院内分泌科
出处 《中国实用医药》 2011年第4期52-53,共2页 China Practical Medicine
关键词 氯沙坦 辛伐他汀 糖尿病肾病 Iovastain Simvastatin Diabetic nephropathy
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献5

  • 1Collins R,Armitage J,Parish S,et al.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial.Lancet,2003,361(9373):2005-2016.
  • 2Qin J,Zhang Z,Liu J,et al.Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.Kidney Int,2003,64(2):565-571.
  • 3Rosario RF,Prabhakar S.Lipids and diabetic nephropathy.Curr Diab Rep,2006,6(6):455-462.
  • 4Maron DJ,Fazio S,Linton MF.Current perspective sonstatins.Circulation,2000:207-213.
  • 5杨光伟,叶山东.他汀类药物对糖尿病肾病保护作用及其机制的研究进展[J].国外医学（老年医学分册）,2006,27(3):126-130. 被引量：8

二级参考文献19

  • 1American Diabetes Association. Management of dyslipidemia in adults with diabetes (Position Statement) . Diabetes Care, 19991 22 (suppl1): s56-s59.
  • 2Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet, 2003, 361 (9374): 2005-2016.
  • 3Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol,2001;21 (6): 449-454.
  • 4Wolffenbuttel BHR, Franken AAM, Vincent HH.Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetesCORALL study. J Intern Med, 2005; 257 (6): 531-539.
  • 5Massy ZA, Kim Y, Guijarro C et al. Low-density lipoprotein-induced expression of interleukin- 6, a marker of human mesangial cell inflammation: Effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun, 2000;267 (2):536-540.
  • 6Ota T, Takamura T, Ando H et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia, 2003;46 (6): 843-851.
  • 7Siddals KW, Marshman E, Westwood M et al. Abrogation of insulin-like growth factor- Ⅰ(IGF-Ⅰ) and insulin action by mevalonic acid depletion:synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem, 2004; 279 (37): 38353- 38359.
  • 8Casey RG, Joyce M, Roche-Nagle G et al. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res, 2005;123 (2):176-181.
  • 9Kunieda Y, Nakagawa K, Nishimura H et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin Ⅱ in cultured rat aortic endothelial cells. Thromb Res, 2003;110 (4): 227-234.
  • 10Economides PA, Caselli A, Tiani E et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab, 2004;89 (2): 740-747.

共引文献7

同被引文献78

  • 1Ka|aitzidis R,Bakris GL. Effects of angiotensin 2 receptor blockers on diabetic nephropathy [ J ]. J Hypertens Suppl,2009,27 (5) : 15 - 21.
  • 2Kouroumichakis I, Papanas N, Zarogoulidis P, et al. Fibrates:therapeutic potential for diabetic nephropathy? European Journal of Internal Medicine,2012,23 (4) : 309 - 316.
  • 3Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of ator- vastatin on kidney outcomes and cardiovascular disease in pa- tients with diabetes: an analysis from the Collaborative Atorvas- tatin Diabetes Study (CARDS). Am J Kidney Dis ,2009,54 (5) : 810 -819.
  • 4Fernandez - Ju6rez G, Barrio V, de Vinuesa SG, et al. Dual blockade of the renin - angiotensin system in the progression of renal disease:the need for more clinical trials. J Am Soc Neph- rol,2006,17(3) :S250 - S425.
  • 5Rosario RF, Prabhakar S. Lipids and diabetic nephropathy. Curt Diab Rep,2006,6(6) :455 -462.
  • 6Tamura Y,Murayama T,Minami M,et al. Differential effect of st- atins on diabetic nephropathy in db/db mice. Int J Mol Med, 2011,28 (5) :683 - 687.
  • 7Nishikawa T, Matsuzawa Y, Suematsu S, et al. Effect of atorvasta- tin on aldosterone production induced by glucose, LDL or angio- tensin II in human renal mesangial cells. Arzneimittelforschung, 2010,60(7) :445 -451.
  • 8Persson PB, Hansell P, Liss P. Pathophysiology of contrast me- dium - induced nephropathy. Kidney Int, 2005,68 ( 1 ) : 14 - 22.
  • 9Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly:the Cardiovascular Health Study. Diabetes,2001, 50(10) :2384 -2389.
  • 10Alber HF, Frick M, Stissenbacher A, et al. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease. Wien Med Woebensehr,2007,157 ( 3 - 4 ) :73 - 78.

引证文献8

二级引证文献61

中国实用医药
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部